Curanex Pharmaceuticals Inc Common Stock (CURX) vs KALA BIO, Inc. (KALA)
A side-by-side comparison of Curanex Pharmaceuticals Inc Common Stock and KALA BIO, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CURX
Curanex Pharmaceuticals Inc Common Stock
$4.87HealthcareDelayed quote: Oct 6, 2026, 1:04 PM EDT
KALA
KALA BIO, Inc.
$0.37HealthcareDelayed quote: Oct 6, 2026, 12:59 PM EDT
Total return — CURX vs KALA
growth of $100 · dividends reinvested · last 1yCURX -93.8% (-93.8%/yr)KALA -99.9% (-99.9%/yr)CURX compounded faster over this window
Log scale — wide-divergence pair
CURX KALA
CURX vs KALA: by the numbers
- •KALA is the larger company ($7M vs $7M market cap).
Metrics side by side
Valuation
| Metric | CURX | KALA |
|---|---|---|
| P/B ratio | 1.44 | 0.79 |
Profitability
| Metric | CURX | KALA |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -218.65% | -111.46% |
| ROIC | -208.39% | -232.05% |
Growth (annualized)
| Metric | CURX | KALA |
|---|---|---|
| Total return CAGR (5Y) | N/A | -85.73% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.